• Research Pipeline🔍
• Drug Development in Autosomal Dominant Polycystic Kidney Disease🔍
• Polycystic Kidney Disease Drug Development🔍
• A new drug candidate can shrink kidney cysts🔍
• PKD Outcomes Consortium 🔍
• Drug Development for Cystic Kidney Diseases🔍
• Polycystic Kidney Disease Outcomes Consortium🔍
• Drug repurposing in autosomal dominant polycystic kidney disease🔍

Research Pipeline - PKD Foundation

Tolvaptan is a medication (taken twice a day as an oral pill) that affects how the kidneys control the concentration of urine. It's been shown to slow down the ...

Drug Development in Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder characterized by relentless growth of innumerable renal cysts bilaterally, ...

Polycystic Kidney Disease Drug Development: A Conference Report

The clinical course of kidney disease in ADPKD is typically marked by a long period of stable glomerular filtration rate (GFR) due to ...

A new drug candidate can shrink kidney cysts | MIT News

A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more ...

PKD Outcomes Consortium (PKDOC)

PKD is marked by a long period of stable kidney function (as measured by the currently accepted endpoints in drug development) during which the kidneys expand ...

Drug Development for Cystic Kidney Diseases

Although one therapy (tolvaptan) has been approved in the United States and other regions for the treatment of ADPKD, the development of clear regulatory ...

Polycystic Kidney Disease Outcomes Consortium

Currently, only one FDA-approved drug (Tolvaptan) exists for ADPKD, but given its mechanism of action and side effects profile (liver toxicity, polyuria), the ...

Drug repurposing in autosomal dominant polycystic kidney disease

Tolvaptan, a vasopressin 2 receptor antagonist, is the only drug approved to treat patients with autosomal dominant polycystic kidney disease ...

Perspectives on Drug Development in Early ADPKD

Diet and lifestyle clearly contribute to the risk of progression. Obesity, higher salt intake, and lower potassium intake have been linked to increased cyst ...

Prioritized polycystic kidney disease drug targets and repurposing ...

Tolvaptan reduces renal cyst growth and kidney function loss, but it is not tolerated by many patients and is associated with idiosyncratic ...

A high-throughput screening platform for Polycystic Kidney Disease ...

Moreover, several drugs originally developed for cancer have shown to ameliorate cyst formation and disease progression in animal models of ...

Computational drug discovery approaches identify mebendazole as ...

Tolvaptan is the only disease-modifying drug approved for the treatment of ADPKD, however its poor side effect and safety profile necessitates the need for the ...

Impact on Industry and Patients: Polycystic Kidney Disease ...

As an accelerator, PKDOC's contributions have enhanced the ADPKD drug development process. TKV was accepted as the basis of approval for JYNARQUE® (tolvaptan), ...

Vertex Announces FDA Clearance of Investigational New Drug ...

ADPKD is the most common inherited kidney disease, with no treatments currently available that address the underlying cause of disease ...

Investigating new treatments for polycystic kidney disease

Organoid models enabled the researchers to study the effectiveness of eukaryotic ribosomal selective glycoside drugs on PKD cyst formation.

Drugs in Clinical Development to Treat Autosomal Dominant ...

Approximately 10% of patients who receive kidney replacement therapy suffer from ADPKD. To date, a vasopressin V2 receptor antagonist (V2RA) is ...

Phase II Clinical Trial Begins for Autosomal Dominant Polycystic ...

Phase II Clinical Trial Begins for Autosomal Dominant Polycystic Kidney Disease Drug Candidate Identified by iPS Cell-based Drug Discovery.

Drug Development in Autosomal Dominant Polycystic Kidney Disease

The burden of ADPKD and its treatment is associated with a significant economic and societal cost. Despite several clinical studies conducted over the past ...

Drug repurposing in autosomal dominant polycystic kidney disease

Tolvaptan, a vasopressin 2 receptor antagonist, is the only drug approved to treat patients with autosomal dominant polycystic kidney disease who have rapid ...

Drug discovery for polycystic kidney disease - Nature

In this review article, we summarize the pathogenesis of PKD, possible drug targets, available PKD models for screening and evaluating new drugs as well as ...